Charles Schwab’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.9M | Buy |
284,971
+116,964
| +70% | +$8.56M | ﹤0.01% | 1832 |
|
|
2026
Q1 | $12.1M | Buy |
168,007
+47,627
| +40% | +$2.71M | ﹤0.01% | 2012 |
|
|
2025
Q4 | $5.09M | Buy |
120,380
+5,716
| +5% | +$320K | ﹤0.01% | 2447 |
|
|
2025
Q3 | $6.52M | Buy |
114,664
+48,735
| +74% | +$1.61M | ﹤0.01% | 2313 |
|
|
2025
Q2 | $1.7M | Sell |
65,929
-29,701
| -31% | -$333K | ﹤0.01% | 2721 |
|
|
2025
Q1 | $975K | Sell |
95,630
-2,114
| -2% | -$27.6K | ﹤0.01% | 2853 |
|
|
2024
Q4 | $1.36M | Buy |
97,744
+799
| +0.8% | +$14.1K | ﹤0.01% | 2803 |
|
|
2024
Q3 | $1.89M | Sell |
96,945
-2,237
| -2% | -$42.6K | ﹤0.01% | 2726 |
|
|
2024
Q2 | $1.84M | Buy |
99,182
+23,961
| +32% | +$505K | ﹤0.01% | 2727 |
|
|
2024
Q1 | $1.05M | Buy |
75,221
+2,293
| +3% | +$24K | ﹤0.01% | 2783 |
|
|
2023
Q4 | $618K | Buy |
72,928
+1,325
| +2% | +$10K | ﹤0.01% | 2990 |
|
|
2023
Q3 | $640K | Buy |
71,603
+4,934
| +7% | +$47.5K | ﹤0.01% | 2956 |
|
|
2023
Q2 | $575K | Sell |
66,669
-13,562
| -17% | -$145K | ﹤0.01% | 2981 |
|
|
2023
Q1 | $846K | Sell |
80,231
-11,515
| -13% | -$348K | ﹤0.01% | 2789 |
|
|
2022
Q4 | $3.11M | Buy |
91,746
+1,127
| +1% | +$54.5K | ﹤0.01% | 2421 |
|
|
2022
Q3 | $4.35M | Buy |
90,619
+3,309
| +4% | +$197K | ﹤0.01% | 2289 |
|
|
2022
Q2 | $4.98M | Buy |
87,310
+24,114
| +38% | +$1.52M | ﹤0.01% | 2188 |
|
|
2022
Q1 | $5.11M | Buy |
63,196
+1,138
| +2% | +$168K | ﹤0.01% | 2271 |
|
|
2021
Q4 | $12.6M | Buy |
62,058
+1,553
| +3% | +$337K | ﹤0.01% | 1882 |
|
|
2021
Q3 | $16.3M | Buy |
60,505
+1,087
| +2% | +$261K | 0.01% | 1732 |
|
|
2021
Q2 | $15.3M | Buy |
59,418
+1,324
| +2% | +$366K | 0.01% | 1765 |
|
|
2021
Q1 | $17.4M | Sell |
58,094
-8,663
| -13% | -$2.7M | 0.01% | 1633 |
|
|
2020
Q4 | $17M | Buy |
66,757
+3,295
| +5% | +$851K | 0.01% | 1518 |
|
|
2020
Q3 | $15.8M | Buy |
63,462
+1,556
| +3% | +$489K | 0.01% | 1370 |
|
|
2020
Q2 | $21.5M | Buy |
61,906
+6,125
| +11% | +$1.91M | 0.01% | 1115 |
|
|
2020
Q1 | $14.9M | Buy |
55,781
+3,557
| +7% | +$1.1M | 0.01% | 1195 |
|
|
2019
Q4 | $16.9M | Sell |
52,224
-17,771
| -25% | -$5.15M | 0.01% | 1330 |
|
|
2019
Q3 | $19.1M | Buy |
69,995
+19,951
| +40% | +$7.32M | 0.01% | 1171 |
|
|
2019
Q2 | $26.7M | Buy |
50,044
+1,834
| +4% | +$920K | 0.02% | 947 |
|
|
2019
Q1 | $24.3M | Buy |
48,210
+1,394
| +3% | +$826K | 0.02% | 986 |
|
|
2018
Q4 | $23.1M | Buy |
46,816
+1,725
| +4% | +$1.04M | 0.02% | 903 |
|
|
2018
Q3 | $41.2M | Sell |
45,091
-14,022
| -24% | -$12M | 0.03% | 630 |
|
|
2018
Q2 | $43.3M | Sell |
59,113
-18,103
| -23% | -$20.9M | 0.03% | 562 |
|
|
2018
Q1 | $123M | Buy |
77,216
+23,718
| +44% | +$30.6M | 0.1% | 203 |
|
|
2017
Q4 | $47.9M | Buy |
53,498
+6,613
| +14% | +$3.91M | 0.04% | 476 |
|
|
2017
Q3 | $16.9M | Buy |
46,885
+3,229
| +7% | +$1.01M | 0.01% | 1055 |
|
|
2017
Q2 | $12.8M | Buy |
43,656
+1,416
| +3% | +$409K | 0.01% | 1177 |
|
|
2017
Q1 | $14.9M | Buy |
42,240
+3,786
| +10% | +$851K | 0.01% | 1025 |
|
|
2016
Q4 | $7.08M | Buy |
38,454
+4,122
| +12% | +$838K | 0.01% | 1508 |
|
|
2016
Q3 | $8.85M | Buy |
34,332
+3,246
| +10% | +$836K | 0.01% | 1255 |
|
|
2016
Q2 | $6.64M | Buy |
31,086
+552
| +2% | +$123K | 0.01% | 1370 |
|
|
2016
Q1 | $6.3M | Sell |
30,534
-19
| -0.1% | -$3.65K | 0.01% | 1365 |
|
|
2015
Q4 | $7.72M | Buy |
30,553
+3,263
| +12% | +$671K | 0.01% | 1199 |
|
|
2015
Q3 | $4.49M | Sell |
27,290
-9,629
| -26% | -$1.7M | 0.01% | 1545 |
|
|
2015
Q2 | $6.93M | Buy |
36,919
+12,973
| +54% | +$2.23M | 0.01% | 1323 |
|
|
2015
Q1 | $3.95M | Sell |
23,946
-1,386
| -5% | -$285K | 0.01% | 1668 |
|
|
2014
Q4 | $5.89M | Sell |
25,332
-8,432
| -25% | -$1.8M | 0.01% | 1320 |
|
|
2014
Q3 | $6.11M | Buy |
33,764
+677
| +2% | +$130K | 0.01% | 1191 |
|
|
2014
Q2 | $6.36M | Sell |
33,087
-2,501
| -7% | -$442K | 0.01% | 1201 |
|
|
2014
Q1 | $6.47M | Buy |
35,588
+6,828
| +24% | +$1.35M | 0.01% | 1121 |
|
|
2013
Q4 | $4.9M | Sell |
28,760
-2,266
| -7% | -$365K | 0.01% | 1272 |
|
|
2013
Q3 | $4.87M | Buy |
31,026
+11,226
| +57% | +$2.08M | 0.01% | 1208 |
|
|
2013
Q2 | $3.55M | Buy |
+19,800
| New | +$3.04M | 0.01% | 1337 |
|
Other funds holding NKTR
TSC
BI
VPC
Charles Schwab's NKTR Position: Q2 2026 in Review
Charles Schwab increased its Nektar Therapeutics (NKTR) stake by 70% in Q2 2026, buying an estimated $8.56M and bringing the position to 284,971 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1832.
Charles Schwab first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $123M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.
- Charles Schwab held 284,971 shares of Nektar Therapeutics worth $19.9M as of Q2 2026.
- Charles Schwab bought 116,964 Nektar Therapeutics shares in Q2 2026, an estimated $8.56M.
- Nektar Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1832 holding.
- Charles Schwab first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Nektar Therapeutics position peaked at $123M in Q1 2018.
- 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.